Upadacitinib for the management of bullous pemphigoid coexisting with psoriasis vulgaris: a case report and literature review

References

• Fang H, Li Q, Wang G. The role of T cells in pemphigus vulgaris and bullous pemphigoid. Autoimmun Rev. 2020;19(11):1. doi: 10.1016/j.autrev.2020.102661.
   Web of Science ®Google Scholar
• Korman NJ. Management of psoriasis as a systemic disease: what is the evidence? Br J Dermatol. 2020;182(4):840–6. doi: 10.1111/bjd.18245.
   PubMed Web of Science ®Google Scholar
• Damsky W, King BA. JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol. 2017;76(4):736–744. doi: 10.1016/j.jaad.2016.12.005.
   PubMed Web of Science ®Google Scholar
• Solimani F, Meier K, Ghoreschi K. Emerging topical and systemic JAK inhibitors in dermatology. Front Immunol. 2019;10(December):2847. doi: 10.3389/fimmu.2019.02847.
   PubMedGoogle Scholar
• Xin P, Xu X, Deng C, et al. The role of JAK/STAT signaling pathway and its inhibitors in diseases. Int Immunopharmacol. 2020;80(October 2019):106210. doi: 10.1016/j.intimp.2020.106210.
   PubMedGoogle Scholar
• Sarny S, Hucke M, El-Shabrawi Y. Treatment of mucous membrane pemphigoid with Janus kinase inhibitor baricitinib. JAMA Ophthalmol. 2018;136(12):1420–1422. doi: 10.1001/jamaophthalmol.2018.3789.
   PubMed Web of Science ®Google Scholar
• Fan B, Wang M. Tofacitinib in recalcitrant bullous pemphigoid: a report of seven cases. Br J Dermatol. 2023;188(3):432–434. doi: 10.1093/bjd/ljac078.
   PubMed Web of Science ®Google Scholar
• Kvist-Hansen A, Hansen PR, Skov L. Systemic treatment of psoriasis with JAK inhibitors: a review. Dermatol Ther (Heidelb). 2020;10(1):29–42. doi: 10.1007/s13555-019-00347-w.
   PubMed Web of Science ®Google Scholar
• Xiao Y, Xiang H, Li W. Concurrent bullous pemphigoid and plaque psoriasis successfully treated with Janus kinase inhibitor baricitinib. Dermatol Ther. 2022;35(10):e15754. doi: 10.1111/dth.15754.
   PubMed Web of Science ®Google Scholar
• Li H, Wang H, Qiao G, et al. Concurrent bullous pemphigoid and psoriasis vulgaris successfully treated with Janus kinase inhibitor tofacitinib: a case report and review of the literature. Int Immunopharmacol. 2023;122(June):110591. doi: 10.1016/j.intimp.2023.110591.
   PubMedGoogle Scholar
• Nash D, Kirchhof MG. Bullous pemphigoid treated with Janus kinase inhibitor upadacitinib. JAAD Case Rep. 2023;32:81–83. doi: 10.1016/j.jdcr.2022.12.006.
   PubMedGoogle Scholar
• Wang N, Yang Q, Liu Y, et al. Upadacitinib in nail psoriasis: a case report. J Dermatolog Treat. 2023;34(1):2246604. doi: 10.1080/09546634.2023.2246604.
   PubMed Web of Science ®Google Scholar
• Borradori L, Van Beek N, Feliciani C, et al. Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2022;36(10):1689–1704. doi: 10.1111/jdv.18220.
   PubMed Web of Science ®Google Scholar
• Abdat R, Waldman RA, de Bedout V, et al. Dupilumab as a novel therapy for bullous pemphigoid: a multicenter case ­series. J Am Acad Dermatol. 2020;83(1):46–52. doi: 10.1016/j.jaad.2020.01.089.
   PubMed Web of Science ®Google Scholar
• Zhang X, Man X, Tang Z, et al. Dupilumab as a novel therapy for bullous pemphigoid. Int J Dermatol. 2023;62(4):e263–e266. doi: 10.1111/ijd.16525.
   PubMed Web of Science ®Google Scholar
• Pesu M, Laurence A, Kishore N, et al. Therapeutic targeting of Janus kinases. Immunol Rev. 2008;223(1):132–142. doi: 10.1111/j.1600-065X.2008.00644.x.
   PubMed Web of Science ®Google Scholar
• Muddebihal A, Khurana A, Sardana K. JAK inhibitors in dermatology: the road travelled and path ahead, a narrative ­review. Expert Rev Clin Pharmacol. 2023;16(4):279–295. doi: 10.1080/17512433.2023.2193682.
   PubMed Web of Science ®Google Scholar
• Duggan S, Keam SJ. Upadacitinib: first approval. Drugs. 2019;79(16):1819–1828. doi: 10.1007/s40265-019-01211-z.
   PubMed Web of Science ®Google Scholar
• Grattan CEH. Evidence of a link between bullous pemphigoid and psoriasis. Br J Dermatol. 1985;113(3):281–283. doi: 10.1111/j.1365-2133.1985.tb02079.x.
   PubMed Web of Science ®Google Scholar
• Kridin K, Ludwig RJ, Schonmann Y, et al. The bidirectional association between bullous pemphigoid and psoriasis: a population-based cohort study. Front. Med. 2020;7(August):1–7. doi: 10.3389/fmed.2020.00511.
   Google Scholar
• Genovese G, Di Zenzo G, Cozzani E, et al. New insights into the pathogenesis of bullous pemphigoid: 2019 update. Front Immunol. 2019;10(JUL):1506. doi: 10.3389/fimmu.2019.01506.
   PubMedGoogle Scholar
• Juczynska K, Wozniacka A, Waszczykowska E, et al. Expression of the JAK/STAT signaling pathway in bullous pemphigoid and dermatitis herpetiformis. Mediators Inflamm. 2017;2017:6716419–6716412. doi: 10.1155/2017/6716419.
   PubMed Web of Science ®Google Scholar
• Kalantari Y, Sadeghi S, Asadi D, et al. A literature review on Janus kinase (JAK) inhibitors for the treatment of immunobullous disorders. Int Immunopharmacol. 2022;110(April):108923. doi: 10.1016/j.intimp.2022.108923.
   PubMedGoogle Scholar
• Griffiths CEM, Armstrong AW, Gudjonsson JE, et al. Psoriasis. Lancet. 2021;397(10281):1301–1315. doi: 10.1016/S0140-6736(20)32549-6.
   PubMed Web of Science ®Google Scholar
• Gómez-García F, Gómez-Arias PJ, Montilla-López A, et al. A scoping review on use of drugs targeting the JAK/STAT pathway in psoriasis. Front Med. 2022;9(February):1–10. doi: 10.3389/fmed.2022.754116.
   Google Scholar
• Alten R, Mischkewitz M, Stefanski AL, et al. Janus kinase ­inhibitors: state of the art in clinical use and future perspectives. Z Rheumatol. 2020;79(3):241–254. doi: 10.1007/s00393-020-00768-5.
   PubMed Web of Science ®Google Scholar